

**Regd. Office :**  
'Zydus Tower',  
Satellite Cross Roads,  
Ahmedabad 380 015. India.  
Phone : +91-79-2686 8100 (20 Lines)  
Fax : +91-79-2686 2368  
www.zyduscadila.com  
CIN:L24230GJ1995PLC025878

Bombay Stock Exchange Limited 1 <sup>st</sup> Floor, P.J. Towers Dalal Street <u>Mumbai – 400 001</u> <b>Kind Attn.:</b> Mr. Sanjay Golecha / Mr. Gopalkrishnan	National Stock Exchange of India Limited Exchange Plaza, 5 <sup>th</sup> Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East) <u>Mumbai – 400 051</u> <b>Kind Attn.:</b> Famroze Pochara Asst. Vice President
<b>Date:</b> August 12, 2015	
<b>Re.:</b> <u>Unaudited financial results</u>	


**Re.:** Unaudited financial results for the quarter ended on June 30, 2015

We are forwarding herewith unaudited financial results for the quarter ended on June 30, 2015 reviewed by Audit Committee and taken on record by the Board of Directors on August 12, 2015 pursuant to Clause 41 of the Listing Agreement; the same may please receive in order.

Thanking you

Yours faithfully

For Cadila Healthcare Limited



**Upen H. Shah**  
**Company Secretary**

**Encl.:** As above

**PART I**
**Statement of Results for the Quarter Ended 30/06/2015**

Rupees in Lacs				Rupees in Lacs			
CONSOLIDATED		COMPANY		CONSOLIDATED		COMPANY	
3 Months ended 30/06/2015 (Unaudited)	Preceding 3 months ended 31/03/2015 (Audited)	3 months ended 30/06/2014 in the previous year (Unaudited)	Previous year ended 31/03/2015 (Audited)	3 Months ended 30/06/2015 (Unaudited)	Preceding 3 months ended 31/03/2015 (Audited)	3 months ended 30/06/2014 in the previous year (Unaudited)	Previous year ended 31/03/2015 (Audited)
Particulars				Particulars			
Sr. No.							
	<b>Income from operations</b>						
	i Gross Sales			177,343	135,609	100,372	476,361
	ii Less: Excise Duty			2,053	1,853	1,681	7,752
	a Net Sales			175,290	133,756	98,691	468,609
	b Other operating income			16,212	11,639	12,588	59,834
	c Total income from operations (net)			191,502	145,395	111,279	528,443
	<b>Expenses</b>						
	a Cost of materials consumed			35,985	29,678	31,655	128,606
	b Purchases of stock-in-trade			10,900	12,666	11,537	44,150
	c Changes in inventories of finished goods, work-in-progress and stock-in-trade			6,108	(536)	(5,189)	(7,598)
	d Employee benefits expense			17,114	15,009	15,176	60,713
	e Depreciation and amortisation expense			5,184	5,539	5,295	21,185
	f Other expenses			49,512	42,282	31,715	149,161
	g Total expenses			124,803	104,638	90,189	396,217
	<b>Profit/ (Loss) from Operations before other income, finance costs and exceptional items (1-2)</b>			66,699	40,757	21,090	132,226
	h Other income			1,491	1,490	1,634	18,521
	<b>Profit/ (Loss) from ordinary activities before finance costs and exceptional items (3+4)</b>			68,190	42,247	22,724	150,747
	i Finance costs			745	1,386	825	4,284
	<b>Profit/ (Loss) from ordinary activities after finance costs but before exceptional items (5-6)</b>			67,445	40,861	21,899	146,463
	j Exceptional items			0	0	0	0
	<b>Profit/ (Loss) from ordinary activities before tax (7-8)</b>			67,445	40,861	21,899	146,463
	k Tax expense			11,870	6,155	2,170	19,351
	<b>Net Profit/ (Loss) from ordinary activities after tax (9-10)</b>			55,575	34,706	19,729	127,112
	l Extraordinary items (net of tax expense)			0	0	0	0
	<b>Net Profit/ (Loss) for the period (11-12)</b>			55,575	34,706	19,729	127,112
	m Pre-acquisition loss transferred to Goodwill arising on consolidation			0	0	0	0
	n Minority interest			0	0	0	0
	<b>Net Profit/ (Loss) after taxes, minority interest and share of profit/ (loss) of associates (13+14+15)</b>			55,575	34,706	19,729	127,112
	o Paid-up equity share capital (Face Value Rs. 5/-)			10,237	10,237	10,237	10,237
	p Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year			414,917	414,917	414,917	442,295
	<b>Earnings per share (before extraordinary items) (Of Rs. 5/- each) (not annualised):</b>						
	a Basic (Rs.)			27.14	16.95	9.64	62.08
	b Diluted (Rs.)			27.14	16.95	9.64	62.08
	<b>Earnings per share (after extraordinary items) (Of Rs. 5/- each) (not annualised):</b>						
	a Basic (Rs.)			27.14	16.95	9.64	62.08
	b Diluted (Rs.)			27.14	16.95	9.64	62.08

**Notes :**

- [1] The above results for the quarter ended on June 30, 2015 were reviewed by the Audit Committee and then approved by the Board of Directors at their meeting held on August 12, 2015.
- [2] The Statutory Auditors of the Company have carried out a "Limited Review" of the above results as per clause 41 of the Listing Agreement.
- [3] In consolidated results, other operating income for the quarter ended June 30, 2015 includes consideration of Rs. 6,666 Lacs (USD 10.5 Millions) received by Zydus Pharmaceuticals (USA) Inc., a wholly owned subsidiary company, on sale and transfer of ownership interest in certain Abbreviated New Drug Applications [ANDAs] for generic drug products.
- [4] Exceptional items in the consolidated results include:

No.	Particulars	Rupees in Lacs		
		3 Months ended 30/06/2015 (Unaudited)	Preceding 3 months ended 31/03/2015 (Audited)	3 months ended 30/06/2014 in the previous year (Unaudited)
a	Provision for various expenses related to the closure of business operators in Japan	0	(143)	118
b	Provision for amount payable to a former supplier for termination of supply contract, pursuant to the order passed by the Hon'ble High Court of Madrid, Spain	0	0	0
c	Payment made under Voluntary Retirement Scheme	211	0	0
			(26)	1,070
			(Audited)	(Audited)

[5] During the quarter, the Company has changed the initial invoking policy for supply of its products to its subsidiary companies. Consequently, there is a one-time impact on consolidated tax expense for the quarter ended June 30, 2015, which is higher by Rs. 6,154 Lacs, though it has no impact on consolidated gross sales and profit before tax.

[6] Figures of previous reporting periods have been regrouped/ reclassified wherever necessary to correspond with the figures of the current reporting period.

[7] The Company has one segment of activity viz. "Pharmaceuticals".

**PART II**

**Select Information for the Quarter Ended 30/06/2015**

3 Months ended 30/06/2015	Preceding 3 months ended 31/03/2015	3 months ended 30/06/2014 in the previous year	Previous year ended 31/03/2015	
51,610,474	51,610,474	51,610,474	51,610,474	A <b>PARTICULARS OF SHAREHOLDING</b> 1 Public Shareholding - Number of shares - Percentage of Shareholding
25.21%	25.21%	25.21%	25.21%	
153,138,046	153,138,046	153,138,046	153,138,046	2 <b>Promoters and Promoter Group Shareholding</b> a Pledged / Encumbered - Number of Shares - Percentage of shares (as a % of the total shareholding of promoter and promoter group) - Percentage of shares (as a % of the total share capital of the company) b Non - encumbered - Number of shares - Percentage of shares (as a % of the total shareholding of Promoter and Promoter group) - Percentage of shares (as a % of the total share capital of the company)
74.79%	74.79%	74.79%	74.79%	
				B <b>INVESTOR COMPLAINTS [In Numbers]</b> Pending at the beginning of the quarter Received during the quarter Disposed of during the quarter Remaining unresolved at the end of the quarter